Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Feb 15, 2024 6:33pm
169 Views
Post# 35883088

RE:FDA Tracker Confirms October 8 date for ONCY

RE:FDA Tracker Confirms October 8 date for ONCYThe FDA tracker cited is a private site created by Joseph Lee ... and by the ONCY PDUFA  example, his "creation" is serously flawed for reasons already provided, simply because no company is able to apply for a supplement BLA (sBLA) without having a biological license already approved. And he would have no insider information on upcoming Accelerated Approvals whatsoever.

https://www.fdatracker.com/about/

ABOUT

FDA Tracker was established in 2011 to help pharma and biotech traders analyze regulatory, financial, and clinical catalysts. Our independent research tools track PDUFA dates, FDA advisory committee meetings, clinical trial results, patent expirations, and cash burn rates for publicly traded companies in the United States.

Founder

Joseph Lee received his PhD in pharmaceutical sciences and pharmacogenomics from UCSF.  As a data scientist, he uses his interdisciplinary background to create new biopharma analytics.  Contact him at jlee@fdatracker.com.


<< Previous
Bullboard Posts
Next >>